BEAM
Beam Therapeutics Inc.
There isn't enough reported data to score BEAM yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
BEAM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
BEAM's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
BEAM PE Valuation
BEAM has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
BEAM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect BEAM's losses to grow, with revenue declining. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
BEAM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.84 | +$3.59 |
| Q2 2026 | -$0.66 | +$3.84 |
| Q1 2026 | -$0.48 | +$4.13 |
| Q4 2025 | -$0.81 | +$3.77 |
| Q3 2025 | -$4.43 | -$2.85 |
| Q2 2025 | -$4.50 | -$2.87 |
| Q1 2025 | -$4.61 | -$3.01 |
| Q4 2024 | -$4.58 | -$2.86 |
BEAM is still losing money, but far less than before: $0.84 per share over the past year, against $7.05 at its worst in mid-2021.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over BEAM on earnings quality, reporting a profit while its opponent remains loss making.
BEAM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $307K | -97% |
| Q2 2026 | $490K | -94% |
| Q1 2026 | $31.7M | +325% |
| Q4 2025 | $114.1M | +280% |
| Q3 2025 | $9.7M | -32% |
| Q2 2025 | $8.5M | -28% |
| Q1 2025 | $7.5M | +0.8% |
| Q4 2024 | $30.1M | -90% |
BEAM's revenue is growing: $307,000 last quarter, down 97% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -46033% | -44726 points |
| Q2 2026 | -25827% | -24408 points |
| Q1 2026 | -338% | +1259 points |
| Q4 2025 | -15% | +317 points |
| Q3 2025 | -1308% | -561 points |
| Q2 2025 | -1419% | -528 points |
| Q1 2025 | -1597% | -192 points |
| Q4 2024 | -333% | -375 points |
BEAM's operating margin was −46033% last quarter, down 44726 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over BEAM on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over BEAM on profitability, with a higher operating margin.
BEAM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$112M | -$25.5M |
| Q2 2026 | -$68.5M | +$11.1M |
| Q1 2026 | -$130.7M | -$23.8M |
| Q4 2025 | -$87M | -$7.7M |
| Q3 2025 | -$86.5M | +$3.2M |
| Q2 2025 | -$79.6M | +$5.4M |
| Q1 2025 | -$106.9M | -$4.8M |
| Q4 2024 | -$79.3M | -160% |
BEAM has burned cash in almost every quarter: −$398M over the past year, against −$352M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over BEAM on cash generation, producing positive trailing cash flow while its opponent burns cash.
BEAM Net Leverage
BEAM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
BEAM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.3 | Neutral |
| Stochastic | 36.5 | Neutral |
BEAM's weekly RSI is 44 (neutral) and its Stochastic is 37 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
BEAM PE vs Healthcare Sector
BEAM has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
BEAM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $25.0 | 3.7% below |
| 20 week MA | $26.9 | 11% below |
| 50 week MA | $27.8 | 14% below |
| 100 week MA | $25.0 | 3.7% below |
| 200 week MA | $26.7 | 10% below |
BEAM is in a downtrend: it's below all five of its weekly moving averages, and 10% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over BEAM on trend strength, trading above more of its moving averages.
BEAM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $20.6 | $87.8 | +326% |
| 2021 | $87.8 | $86.5 | -1.5% |
| 2022 | $86.5 | $40.4 | -53% |
| 2023 | $40.4 | $27.2 | -33% |
| 2024 | $27.2 | $26.6 | -2.3% |
| 2025 | $26.6 | $28.0 | +5.2% |
| 2026 YTD | $28.0 | $24.0 | -14% |
BEAM's yearly returns have swung widely, from +326% in 2020 to −53% in 2022. It's down 14% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over BEAM on returns for 2026, with the stronger performance.